ProCE Banner Activity

How I Treat Patients With EBV-Associated Posttransplant Lymphoproliferative Disease

Clinical Thought
How are you managing patients with EBV-associated posttransplant lymphoproliferative disease? Read this commentary for my approach.

Released: December 06, 2021

Expiration: December 05, 2022

No longer available for credit.

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Atara Biotherapeutics

Bayer Healthcare Pharma

BeiGene Ltd

Epizyme

Genentech, a member of the Roche Group

Genmab US

Incyte Corporation

Karyopharm Therapeutics

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received funds for research support from Acerta/AstraZeneca, Celgene/Bristol-Myers Squibb, Epizyme, Incyte, Kite, Loxo, Novartis, and Seattle Genetics and consulting fees from AbbVie, Acerta/AstraZeneca, Conjupro, Janssen/Pharmacyclics, Johnson & Johnson, Kite, Morphosis, Oncternal, Roche/Genentech, and Vaniam Group.